Study: NCT03718390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Formulation A (37/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Formulation A (37/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Formulation A (37/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Formulation A (37/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Formulation A (37/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Formulation B (46/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Formulation B (46/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Formulation B (46/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Formulation B (46/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Formulation B (46/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: Formulation C (37/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: Formulation C (37/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: Formulation C (37/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: Formulation C (37/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: Formulation C (37/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D
Description: Formulation D (46/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D
Description: Formulation D (46/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D
Description: Formulation D (46/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D
Description: Formulation D (46/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D
Description: Formulation D (46/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E
Description: Placebo Capsule containing microcrystalline cellulose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E
Description: Placebo Capsule containing microcrystalline cellulose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E
Description: Placebo Capsule containing microcrystalline cellulose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E
Description: Placebo Capsule containing microcrystalline cellulose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E
Description: Placebo Capsule containing microcrystalline cellulose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: Endoscopy at 2 hours post dosing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: Endoscopy at 2 hours post dosing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: MRI will be performed on specified days according to protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: MRI will be performed on specified days according to protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: MRI will be performed on specified days according to protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: MRI will be performed on specified days according to protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: MRI will be performed on specified days according to protocol